GO
Loading...

Medicine

More

  • Researcher who found cause of Lyme disease dies Thursday, 20 Nov 2014 | 9:52 AM ET

    HAMILTON, Mont.— The Swiss-born researcher who gained international recognition for discovering the bacteria that causes Lyme disease has died in western Montana. A spokesman at the Daly-Leach Chapel said Wilhelm "Willy" Burgdorfer died from complications of Parkinson's disease Monday in Hamilton. He went to the Rocky Mountain Laboratory in Hamilton as a...

  • Report: Global obesity costs hits $2 trillion Thursday, 20 Nov 2014 | 5:45 AM ET

    LONDON— The global cost of obesity has risen to $2 trillion annually— nearly as much as smoking or the combined impact of armed violence, war and terrorism, according to a new report released Thursday. The McKinsey Global Institute consulting firm's report focused on the economics of obesity, putting it among the top three social programs generated by human...

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Nov 19- Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash. Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate...

  • Early statin use may give long-term heart benefits Wednesday, 19 Nov 2014 | 2:49 PM ET

    CHICAGO— Taking a cholesterol-lowering drug for five years in middle age can lower heart and death risks for decades afterward, and the benefits seem to grow over time, a landmark study of men in Scotland finds. Chris Packard of the University of Glasgow in Scotland. The long-term results were discussed at an American Heart Association conference that ends...

  • Gift of sight     Wednesday, 19 Nov 2014 | 1:41 PM ET

    Second Sight's main product "The Argus" has been helping people who are blind see again. Second Sight patient Fran Fulton, and Second Sight CEO Dr. Roger Greenberg, discuss the technology.

  • NTSB recommends better sleep disorder screening Wednesday, 19 Nov 2014 | 9:31 AM ET

    NEW YORK— Federal regulators who concluded that an engineer's sleep apnea caused a deadly train derailment in New York adopted several recommendations Wednesday for better screening of such disorders, including a call for improved physician training. The National Transportation Safety Board, meeting in Washington, approved all the conclusions and...

  • Nov 19- Synergy Pharmaceuticals Inc said its experimental drug for opioid-induced constipation was found safe and effective in a mid-stage trial. Synergy Pharmaceuticals shares were up 8 percent in premarket trading. The drug SP-333 showed statistically significant improvement in spontaneous bowel movement in the fourth week of treatment, compared...

  • Nov 19- Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash. Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate...

  • Study will test survivors' blood to treat Ebola Tuesday, 18 Nov 2014 | 10:02 PM ET

    The Bill& Melinda Gates Foundation is giving $5.7 million to scale up production of the treatments for the project in Guinea and other Ebola-affected countries in Africa. Besides helping Ebola patients now, plasma "could be a tool for a future epidemic as well" from different viruses, Microsoft co-founder Bill Gates said in an interview with The Associated...

  • Trading 3-D: Pro loves HPQ     Tuesday, 18 Nov 2014 | 5:17 PM ET

    The "Fast Money" traders dig into the play on 3-D printing companies Hewlett-Packard and Organovo.

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer to launch a new bid. AstraZeneca, which saw off a $118 billion approach from Pfizer in May, is his...

  • LONDON, Nov 18- Here are some key facts about avian influenza, after cases of H5N8 bird flu were detected on farms in Germany and the Netherlands:. The World Organisation for Animal Health says animal feed can be another factor in transmission of the disease-- if wild birds and others have access to the same feed-- as well as equipment and clothing.

  • Nov 18- CytRx Corp said the U.S. Food and Drug Administration placed a hold on enrolling new patients in clinical trials of its experimental cancer drug after a patient died, sending the company's shares down 11 percent in premarket trading. Patients already enrolled in the trials, currently in mid stage, will continue receiving the treatment, CytRx said.

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs at an investor day on Tuesday, aiming to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May. AstraZeneca is his biggest holding.

  • CHICAGO, Nov 17- An experimental heart failure medicine from Novartis that previously showed it reduced death and hospitalizations also curtailed worsening of symptoms, need for additional therapy and emergency room visits, adding to evidence that it will become the drug of choice once approved. The Novartis drug, expected to become a multibillion-dollar...

  • Outbreaks like Ebola will happen again: NIH Monday, 17 Nov 2014 | 3:57 PM ET
    File photo: A young man, dressed in a biohazard costume, stands on the corner of 546 West 147th Street in October 2014 in New York City after an American doctor carrying the ebola virus was admitted to Bellevue Hospital

    NIH's Dr. Francis Collins and Milken Institute Chairman Mike Milken make the case for medical research funding to stop outbreaks like Ebola.

  • Advances in medical research     Monday, 17 Nov 2014 | 2:13 PM ET

    Discussing research funding for diseases, as well as Ebola, with Michael Milken, Milken Institute Chair, and Dr. Francis Collins, NIH director.

  • CHICAGO, Nov 17- After years of uncertainty, a nearly decade-long study showed that Merck& Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin. Christopher Cannon, lead investigator of the 18,144- patient Improve-It study presented at the American Heart Association...

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...